Genelux (GNLX) Non Operating Investment Income (2024 - 2026)
Genelux's (GNLX) quarterly Non Operating Investment Income came in at -$14000.0 in Q1 2026, up 60.0% year-on-year from -$8750.0 in Q1 2025, and down 1500.0% quarter-over-quarter from $1000.0 in Q4 2025.
Genelux (GNLX) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Genelux's Non Operating Investment Income history runs 3 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- On a quarterly basis, Non Operating Investment Income rose 60.0% year-over-year to -$14000.0 in Q1 2026; TTM through Mar 2026 was -$34000.0, a 200.0% decrease from a year earlier, with the FY2025 full-year figure at -$55000.0, down 210.0% from the prior year.
- Non Operating Investment Income eased to -$14000.0 in Q1 2026 per GNLX's latest filing, from $1000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $135000.0 in Q3 2024 and bottomed at -$60000.0 in Q4 2024.
- The 3-year median for Non Operating Investment Income is -$14000.0 (2026), against an average of -$2111.1.
- Biggest YoY gain for Non Operating Investment Income was 101.67% in 2025; the steepest drop was 333.33% in 2025.
- Year by year, Non Operating Investment Income stood at -$60000.0 in 2024, then surged by 101.67% to $1000.0 in 2025, then sank by 1500.0% to -$14000.0 in 2026.
- Per Business Quant, the three latest GNLX Non Operating Investment Income figures stand at -$14000.0 (Q1 2026), $1000.0 (Q4 2025), and $5000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | - |
| 10 | Genelux | 130.02 Mn | 130.02 Mn | - | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |